Please assess the completion status of the following clinical trial:

Trial Title: Impact of Liraglutide 3.0 on Body Fat Distribution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 35 years~* Able to provide informed consent~* BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with metabolic syndrome~* Metabolic syndrome is defined as at least three of the following:3~  1. waist circumference \> 102 cm (40 in) in men and 88 cm (35 in) in women~ 2. triglycerides \> 150 mg/dL or on treatment for hypertriglyceridemia~ 3. HDL cholesterol \< 40 mg/dL in men and \< 50 mg/dL in women~ 4. blood pressure \> 130/85 mmHg or on treatment for hypertension~ 5. fasting glucose \> 100 mg/dL~Exclusion Criteria:~* Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists (including liraglutide, exenatide or others as they become available), dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin within the last 3 months.~* Receipt of any anti-obesity drug or supplement within 1 month prior to screening for this trial.~* Self-reported or clinically documented history of significant fluctuations (\>5% change) in weight within 3 months prior to screening for this trial.~* History of diabetes mellitus (type 1 or 2) or on treatment with anti-diabetes medication.~* History of chronic pancreatitis or idiopathic acute pancreatitis (current or prior history).~* History of gallbladder disease (cholelithiasis or cholecystitis).~* Chronic kidney disease stage III or greater (eGFR\<60 mL/min).~* Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome).~* Current or history of treatment with medications that may cause significant weight gain, within 1 month prior to screening for this trial, including systemic corticosteroids (except for a short course of treatment, i.e., 7- 10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g., imipramine, amitryptiline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium).~* Diet attempts using herbal supplements or over-the-counter medications within 1 month prior to screening for this trial.~* Current participation in an organized weight reduction program or within the last 1 month prior to screening for this trial.~* Participation in a clinical trial within the last 3 months prior to screening for this trial.~* Familial or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.~* Personal history of non-familial medullary thyroid carcinoma.~* History of Major Depressive Disorder within the last 2 years.~* History of other severe psychiatric disorders, e.g., schizophrenia, bipolar disorder.~* Any lifetime history of a suicide attempt.~* A history of any suicidal behavior in the last month prior to randomization.~* Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the Investigator.~* Known or suspected hypersensitivity to trial product(s) or related product(s).~* Known or suspected abuse of alcohol or narcotics.~* Language barrier, mental incapacity, unwillingness or inability to understand.~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods. These include abstinence and the following methods: diaphragm with spermicide, condom with spermicide (by male partner), intrauterine device, sponge, spermicide, Norplant®, Depo-Provera® or oral contraceptives.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Liraglutide 3.0 mg (Type: EXPERIMENTAL): Drug: Liraglutide Active Drug~Other Names:~* Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection.
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~* Placebo~* Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete